Supreme Court Faces Choice on Pay-for-Delay Cases

The FTC Thursday asked the Supreme Court to take up and overturn an 11th Circuit Court’s decision that upheld the legality of reverse patent settlements between branded drug makers and generic competitors. The FTC argues the 11th Circuit erred when it ruled against the commission in its challenge to Watson Pharmaceuticals’ and Abbott Laboratories’ agreement to delay a generic version of testosterone replacement AndroGel.
Drug Industry Daily